Market Update (NYSE:BSX): Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

[PR Newswire] – MARLBOROUGH, Mass., Nov. 30, 2015 /PRNewswire/ — Boston Scientific (BSX) has received United States (U.S.) Food and Drug Administration (FDA) approval and CE Mark for the AngioJet™ ZelanteDVT™ thrombectomy catheter . . . → Read More: Market Update (NYSE:BSX): Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter Similar Articles: Stock Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Announces CE Mark for the Vercise™ Primary Cell Deep Brain Stimulation System Market Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Bronchial Thermoplasty Treatment Recognized By American College Of Allergy, Asthma And Immunology Market Update: Boston Scientific Corporation (NYSE:BSX) – Boston Scientific Launches The Precision Novi™ Spinal Cord Stimulator System in Europe
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.